Abbreviations used: AD, Alzheimer disease; BPSD, behavioral and psychological symptoms of dementia; MWM, Morris water maze; scFv, single chain variable Fragment. to the treatment, five-month-old female animals, corresponding to early stages of the disease, showed the first BPSD-like behaviors as assessed in the MWM. These behaviors included long-and short-term learning and memory deficits and high swimming navigation speed. After a single intraperitoneal dose of scFv-h3D6 the swimming pattern was reversed to normal levels and the learning and memory deficits were ameliorated. Brain tissues of these animals revealed global decrease of Aβ oligomers in the cortex and olfactory bulb after treatment, but this was not seen in the hippocampus and cerebellum. In the untreated 3xTg-AD animals we described an increase of both apoJ and apoE concentrations in the cortex, as well as an increase of apoE in the hippocampus. Interestingly, treatment significantly recovered the nonpathological levels of these apolipoproteins. In conclusion, our results suggest that the benefit of scFv-h3D6 occurs at both behavioral and molecular levels.
INTRODUCTION
Amyloid β immunotherapy has shown promises in the treatment of Alzheimer Disease (AD), as indicated by the implementation of ongoing set of clinical trials 1 . The effectiveness of active immunization with Aβ-peptide in removing amyloid plaques, was clearly shown in the noted AN-1792 clinical trial 2 . Although the occurrence of neuroinflammatory complications halted this trial 3 , follow-up of the immunized patients revealed slowing down of cognitive decline, even one year after administration of the last doses 4 . The main drawback of active immunotherapy is the inability to intervene once immune system is activated; this makes passive immunotherapy (administering Aβ-directed antibodies) an attractive alternative.
Humanized murine monoclonal antibody AAB-001 (mAb-h3D6), or Bapineuzumab, which targets the N-terminal 1-5 residues of the Aβ peptide, is being tested in several clinical trials 5 . In Phase II trials, besides vasogenic edema, side effects of Bapineuzumab were mostly mild and transient. The observed edema was thought to be dose-related and more likely to occur in APOE4 carriers. However, in subsequent Phase III trials, which avoided high doses of bapineuzumab and recruited only APOE4 non-carriers, results obtained were still disappointing hence the trial was stopped in August 2012 6 .
In order to avoid meningoencephalitis, vasogenic edema and micro-cerebral hemorrhages which can occur with the use of complete antibodies, the use of singlechain variable fragments (scFv); antibodies devoid of Fc portion and incapable of directly activating microglia, is becoming an attractive therapeutic strategy [7] [8] [9] . We previously described how to obtain recombinant scFv-h3D6, a single chain variable fragment derived from mAb-h3D6 5, 10, 11 , which precludes cytotoxicity of Aβ 1-42 -oligomers
A u t h o r ' s d r a f t v e r s i o n
ScFv-h3D6 reverses AD hallmarks in 3xTg-AD mice in SH-SY5Y neuroblastoma cell-culture, by withdrawing them from the amyloid pathway 12 . Since evidence suggests that therapeutic interventions that reduce Aβ fibrils at the cost of augmenting non-fibrillar Aβ assemblies, including Aβ oligomers, could be harmful 13 targeting Aβ-oligomers, rather than amyloid plaques, is highly recommended 14 .
Our results from cell-culture studies of scFv-h3D6 treatment led us to investigate its disease prevention potential in an in vivo model of AD. The triple-transgenic mouse for Alzheimer disease (3xTg-AD) harboring APP Swe, PS1 M146V , and tau P301L transgenes, represents a unique animal model, which mimics both amyloid and tau AD neuropathologies in an age-dependent manner and in disease-relevant brain regions 15 .
At early stages of the disease, immunohistochemical presence of intraneuronal Aβ can be detected in the cortex, hippocampus and amygdale with this demonstrable at 4 months of age [15] [16] [17] . At these early stages of the disease the model mimics the first "behavioral and psychological symptoms of dementia (BPSD)" which are followed by impairment of cognition [18] [19] [20] [21] . By 6 months of age, studies have reported the presence of deficits at the electrophysiological, synaptic and cholinergic levels as well.
The present work aimed to study the effects of intraperitoneal administration of scFvh3D6 in 3xTg-AD females on some behavioral and molecular aspects at early stages of Alzheimer disease.
ScFv-h3D6 ameliorates AD hallmarks in 3xTg-AD mice
RESULTS
BPSD-like symptoms before the treatment. As detailed in Table 1, the corner and the open-field tests evidenced that, at 5 months of age, the first BPSD-like symptoms were already apparent in the 3xTg-AD mice. Thus, in the corner test, these mice exhibited an anxious-like flight behavior as measured by increased number of corner visits p<0.05] . In the open-field test, the same animals exhibited freezing behavior (latency of initial movement) and impaired thigmotaxis (latency to leave the center and to reach the periphery). As illustrated in Fig. 1 , reduced exploratory activity was observed at different times of the test and in the total accumulated counts in both horizontal and vertical locomotor activities ( Fig. 1A and B, respectively). No differences were found in the other variables.
Assessment of behavioral effects of the treatment. Fig. 2 On the probe trial (see Fig. 3 (Fig. 4 and Table 2 ). That is, 'scanning' and 'random swimming' were the most frequent strategies in all the groups while 'wall hugging' and 'flotation' were only observed in the untreated NTg and 3xTg-AD mice, respectively. 'Direct swims' and 'focal searching' were more characteristic of NTg animals and scarcely seen in the groups of 3xTg-AD mice. The treatment improved the search strategies in both genotypes, in the case of 3xTg-AD by reducing the non-goal directed 'chaining' while in the NTg mice the benefit was obtained by increasing 'direct swims'.
Effect of scFv-h3D6 in the Aβ-aggregation profile in vivo. Mice subjected to the behavioral studies were subsequently sacrificed and several brain subregions, hippocampus, cortex, olfactory bulb and cerebellum, dissected to prepare protein extracts of each group as described in the Materials and Methods Section. Fig. 5 depicts an illustrative immunoblotting analysis with 6E10 antibody of the soluble Aβ-amyloid oligomers from extracellular extracts (TBS fraction). Medium-molecular-mass assemblies (>10kDa) that might represent Aβ oligomers were observed. This species pattern were unaltered when the initial SDS-PAGE did not contain 8M urea (not shown), suggesting that these species are held together by urea-resistant hydrogen bonding. In agreement with other studies 9, 22, 23 , multiples of trimeric Aβ oligomers were detected, i.e. dodecamers, nonamers, hexamers and trimers. Additionally, sAPPα (secreted form of APP by α-secretase cleavage) was also detected.
Aβ-aggregation profiles for NTg mice did not change upon scFv-h3D6 treatment.
Mouse sAPPα, dodecamers, nonamers, and hexamers of Aβ-peptide were detected in all of the samples, being the profile characteristic of the studied brain subregion. It is A u t h o r ' s d r a f t v e r s i o n essential to note that other studies have also detected these mouse species with 6E10 antibody 22 . Similar species were seen in the 3xTg-AD mice; although human sAPPα has higher mobility than mouse sAPPα and the relative abundance of each oligomer was dramatically increased. In fact, since mouse oligomers are being detected in the NTg mice, this evident increase is due to the oligomers being processed from human sAPPα.
As expected, human sAPPα was not detected in the cerebellum, and scFv-h3D6 treatment did not change the profile pattern of the oligomeric species in this area. In the hippocampus, human sAPPα was clearly detected, although the profile pattern of the oligomeric species upon scFv-h3D6 treatment did not change. In contrast, the treatment changed the aggregation profile of the Aβ-peptide in the cortex and in the olfactory bulb. Both cortex and olfactory bulb showed a dramatic decrease in dodecamers, nonamers, and hexamers levels ( Fig. 5 ). It was also likely that the trimer detected in the untreated cortex disappeared upon scFv-h3D6 treatment.
Since the intracellular Aβ has been proposed to be responsible for the first behavioral symptoms observed in 3xTg-AD transgenic mice 15, 18, 19, 24 , the intracellular protein (1% Triton fraction) was analyzed by immunoblotting. No significant change in the profiles was found between treated and non-treated groups (Fig. 6 ). Mainly α-APP and trimeric
Aβ were detected in the hippocampus; whereas the band for dodecamers was rather tiny and those for nonamers and hexamers were not detected. In the cortex only α-APP was detected, whereas in olfactory bulb and cortex any band was observed. Similarly, ApoE concentration was increased in hippocampus (1.7 folds) and cortex (1.8 folds) of 3xTg-AD mice when compared to NTg animals, and scFv treatment clearly restored the non-pathological levels in both areas (Fig. 7B ). The level of apoE in olfactory bulb and cerebellum did not show significant differences.
A u t h o r ' s d r a f t v e r s i o n

DISCUSSION
We recently showed that an antibody fragment, the single-chain variable fragment scFv-h3D6, has the ability to prevent the toxicity induced by the Aβ peptide in human neuroblastoma cell-cultures 12 .
In the present work, the scFv-h3D6 in vivo effects was studied in the triple-transgenic 3xTg-AD mouse model of Alzheimer disease at 5 month of age, which corresponds to early stages of the disease 15 . The therapeutical potential of a single i.p. dose of 85 µg scFv-h3D6 was assessed in females since (i) this route of administration enables an easy translation to humans, and (ii) females have been reported to better exhibit the cognitive and BPSD-like symptoms of the disease 16, [19] [20] [21] .
ScFv-h3D6 treatment improved cognition and reversed BPSD-like symptoms.
Before the treatment, we confirmed the presence of BPSD-like symptoms 19, 27 and determined the level of behavioral disturbances of 3xTg-AD animals at early stages of the disease as compared to NTg mice. In agreement with our previous reports [19] [20] [21] 27 , anxious-like behavior was observed in the corner test, were the novelty of the homecage induced an increased number of corner visits and rearings as a fight-or-flight copying with stress strategy. With the progression of the disease or under more anxiogenic experimental conditions, like those of the open-field test, this neophobia is expressed as freezing and reduced activity 19 . Thus, in the subsequent behavioral test, neophobia to the white and illuminated open arena was expressed as an initial freezing behavior, which was, among all, the most sensitive variable to show the genetic differences between 3xTg-AD and the NTg mice. The initial fear was followed by an extra delay in all the sequence of behavioral events that usually occur in this test: the exit of the centre to reach the periphery, the start of vertical exploratory activity and the self-grooming behavior which starts as soon as the main exploratory activity slows down. A clear reduction of horizontal and vertical components of locomotor activity was A u t h o r ' s d r a f t v e r s i o n also observed. Thereafter, these results confirming the presence of behavioral disturbances were also used as criteria to allocate, for each genotype, the mice in the two treatment groups in a counterbalanced manner 28 .
In order to assess the effects of scFv-h3D6 on cognition and, indirectly, on some BPSD-like symptoms, animals were submitted to a series of paradigms in the MWM 29 .
The tests started with a process of acquisition in the cue learning task which is useful as a first experience in the maze in fearful animals 19 . The performance was optimal in all the groups, with the intramaze cue facilitating the localization of the platform. The lack of genotype differences in this task allowed us to discard the possible confounds of motivational or sensoriomotor differences. All the animals were able to achieve the same level of post-habituation baseline at V14 which emphasized the subsequent results. In the first trial of the place task, the hidden platform and the unexpected change in the usual platform position introduced a certain degree of difficulty to the test. This is shown by the animal's insistence on looking for the platform in the previous location, and thus needing more time and covering more distance, before finding the new position as compared to the previous sessions. Therefore, the genotype effect found in this first trial of the place task was indicative of differences in long-term memory and worse behavioral flexibility in the 3xTg-AD mice. The results were reinforced by the longer distance covered to find the platform, both at the beginning and the end of the place learning task, only shown by the untreated 3xTg-AD mice while the 3xTg-AD animals treated with scFv-h3D6 showed a normal behavior.
Another finding at the behavioral level was the ability of the scFv-h3D6 treatment to reverse the increased swimming speed shown by 3xTg-AD animals into a normalized pattern. This hyperactive swimming pattern was previously characterized 20 and it is considered a common BPSD-like symptom in this animal model since these animals also show hyperactivity in non-anxiogenic conditions 19 , including increased voluntary
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running activity in wheels 21 . Therefore, among all, the effectiveness of scFv-h3D6 on swimming speed provided the most striking finding because it was a consistent phenomenon all through the different trials of the test. Moreover, this is the first time that a treatment modality completely reverses this behavioral hallmark of 3xTg-AD mice, unlike other cases where treatment success modifying swimming speed was not as clearly consistent and effective 20, 21 . It is also interesting to note that the benefits of scFv-h3D6 were extended to the NTg mice, which may suggest the putative benefits of scFv-h3D6 in the normal population as well. In this sense, AD-purposed treatments targeting Aβ processing have also been shown to act as cognitive enhancers in NTg mice (i.e.
28
). The time effect in the latency and the distance in both the cue and place learning tasks is mostly related to short and long-term hippocampal-dependent learning processes. In contrast, the time effect in the navigation speed could be understood as a result of a more goal-directed navigation ability, thanks to the prior experiences 20 .
Interestingly, the increased swimming speed and the search strategies observed in the 3xTg-AD mice in the removal test confirmed the observations obtained in the previous paradigms. Altogether, these results reinforce the fact that behavioral pattern of 3xTg-AD at 5 month of age is already disrupted, as shown by the presence of BPSD-like symptoms and poorest cognitive performance. This included observed increased swimming speed and cognitive impairments mostly affecting long-term memory, although some short-term alterations could be observed. The present results suggest that scFv-h3D6 can be a promising therapeutic strategy and further studies are needed to extent these data.
ScFv-h3D6 treatment eliminated Aβ-oligomers.
It is now widely accepted that soluble Aβ-oligomers are the cause of loss of synapses and the neuronal injury, characteristic of Alzheimer disease 14, 30 . This hypothesis explains the lack of correlation between cognitive decline and the presence of amyloid plaques 31 . Therefore, it makes sense to develop strategies to promote their elimination, a fact that is supported by the finding that therapeutic interventions that reduce Aβ fibrils at the cost of augmenting Aβ oligomers could be harmful Despite the fact that 6E10 antibody should theoretically detect all forms Aβ, we only detected αAPPα and multiples of trimeric Aβ oligomers (dodecamers, nonamers, hexamers and trimers). This could be due to the presence of low molecular weight species (mainly monomers and dimers) being outside the lower limit of detection of our methodology or to their total absence. Interestingly, the oligomeric species detected in the extracellular extracts, which were decreased upon treatment as mentioned above, are those that have been related to the pathology of the disease in the literature. . Also, some groups state that intracellular Aβ is not an indicator of cognitive decline neither in AD nor DS because its level is maintained during the progression of both diseases 37 . In any case, AD dementia strongly correlates with soluble Aβ level (i.e. 31 ), which is clearly diminished in the cortex and olfactory bulb of five-month-old 3xTg-AD females upon scFv-h3D6 treatment.
ScFv-h3D6 treatment restored clusterin and apoE levels.
In this work we found increased levels of clusterin and apoE in the cortex of 3xTg-AD animals, together with an increased level of apoE in hippocampus, and, more interestingly, the restoration to non-pathological levels upon scFv-h3D6 treatment. The There is strong evidence that clusterin and apoE are regulated in a cooperative manner (DeMattos et al., 2004). Non-neuronal cell types, most notably astroglia and microglia, are the primary producers of the lipid transporter apoE, while neurons preferentially express apoE receptors. ApoE is found to colocalize with amyloid-β and plays a role in enhancing its clearance and degradation 44, 45 . In fact, the human APOE4 allele increases the risk of developing late-onset AD plausibly because it binds Aβ with approximately 20-fold lesser avidity than the more abundant allele APOE3
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46
. APOE4-specific changes in Aβ accumulation have also been recently described in EFAD-Tg mice. 47 On the other hand, haploinsufficiency of human APOE reduces amyloid deposition in a mouse model of Aβ amyloidosis and results in significantly decreased amyloid plaque deposition and microglial activation. 48 , suggesting a relationship
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between inflammation and apoE. From our results, it is likely that the opposite is also true: targeting Aβ-oligomers with scFv-h3D6 has diminished them and, as a consequence, apoE levels have been restored. This is of importance, because, although further studies with scFv-h3D6 are required, neuroinflammation was not likely to occur as a side effect. This would be in agreement with other studies claiming that immunotherapy with scFv molecules is safer than that with the complete antibodies [7] [8] [9] .
The suggested benefits of scFv-h3D6 at the behavioral level, its capability for eliminating Aβ oligomers and to restore clusterin and apoE levels in the 3xTg-AD model of Alzheimer disease encourages us to further investigate its therapeutic potential.
MATERIALS AND METHODS
Animals
Triple-transgenic 3xTg-AD mice harboring PS1/ M146V, APP Swe and tau P301L transgenes were genetically engineered at the University of California Irvine, as previously described 15 . Briefly, two independent transgenes (encoding human APPSwe and human tauP301L, both under control of the mouse Thy1.2 regulatory element) were coinjected into single-cell embryos harvested from homozygous mutant PS1M146V
knock-in (PS1KI) mice. Since the PS1 knock-in mice were originally generated in a hybrid 129/C57BL6, this hybrid was used as the control strain, h light: dark cycle starting at 08:00).
Production of scFv-h3D6
ScFv-h3D6 was recombinantly expressed in E. coli and purified as previously described 12 .
It is important to note that lipopolysaccharides (LPS), the major endotoxins of gram-negative bacteria, were removed from the protein by using Detoxi-Gel Endotoxin Removing columns (Thermo Scientific).
Experimental design
Animals were assessed in the corner (CT) and open-field (OF) tests in order to
determine the level of behavioral disturbances shown by 3xTg-AD mice before the treatment and as compared to age-and gender-matched NTg mice 19 . Thereafter, mice
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were allocated in two treatment groups counterbalanced on the basis of the mean locomotor activity recorded in these tests 28 ).
Animals were treated with a single intraperitoneal dose of 85 μg scFv-h3D6 or vehicle (PBS-buffer). Twenty-four hours after the administration, the animals were assessed during 4 consecutive days for cognition and BPSD-like behaviors in a series of MWM paradigms (MWM) 19 . Behavior was evaluated by both direct observation and analysis 
Behavioral assessment prior to the treatment
Corner test
Neophobia to a new home-cage was evaluated in the corner test for 30 seconds.
Animals were individually placed in the center of a clean standard home-cage (Makrolon, 35 x 35 x 25cm) filled with wood shave bedding. Number of corner visits, latency to realize the first rearing, and the number of rearings were recorded.
Open-field test
Immediately after the corner test, mice were placed in the centre of the apparatus (home-made, wooden, white, 55x55x25 cm high) and observed for 5 min. Horizontal 
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Emotional behaviors such as self-grooming behavior (latency, number, and duration of groomings), number of defecations and presence/absence of urine were also measured.
Assessment of behavioral effects of the treatment
Morris water maze tests
The effects of the treatment on the cognitive abilities of the animals were assessed in three paradigms for learning and memory in the Morris water maze (MWM) 29 consisting of one day of cue learning with a visual platform (V), three days of place task for longterm and short-term spatial reference memory with a hidden platform (PT) followed, after removal of the platform (RM), by one probe trial for short-term memory. The mice were trained to locate a platform (7 cm diameter) in a circular pool (Intex Recreation
Corp., Calif., USA; 91cm diameter, 40 cm height, 25ºC opaque water) located in a black test room with distal cues. Animals failing to escape within 90 s were manually guided to the platform. In the trials with platform, all animals stayed on it for 5-10 s before being removed. Immediately after, the animals were dried and then placed in a holding cage with a heating pad to prevent hypothermia.
Day 1, Cue learning with a visual platform
On the first day, animals were trained to criterion (90% escaping under 60s). This required four visible platform trials (V1-V4) in a single day. The last visible platform trial of any animal is considered to be its post-habituation baseline, and was designated V4
(visible platform trial 4). Intertrial interval was 30 minutes. The visible platform remained in the same place for all of the trials and was outlined by a black and white stripped flag with high contrast to the white background made by the addition of white, non-toxic tempera paint. Animals were delivered to either the west or east quadrant (the target quadrant being designated as north) in a random manner for each trial as these are
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equidistant from the target. High contrast visual cues were placed on the wall of the pool in each quadrant.
Day 2 to day 4, Place learning with a hidden platform
Twenty-four hours after the last visible platform trial, the animals were tested in a series of three hidden platform trials (PT1-PT3). Animals were delivered to either the west or east quadrant and the target quadrant being designated as south, that is, reversal to the location in the previous paradigm. As before, the trials were staggered in time to ensure a stable inter-trial interval of about 30 min and each trial was a maximum of 90 s long.
Day 4, Removal
In order to measure the retention and level of accuracy of the precise location of the platform position achieved, the animals were allowed to swim in the probe trial or 'removal' 2 h after the end of the last session of the place task. The procedure consisted of removing the platform from the maze and releasing the mouse from the north starting point and letting the animal navigate for 60s.
During the trials of the learning tasks, the escape latency was measured with a stopwatch. In all trials, the trajectories were recorded and analyzed using the SMART system 2.5.14 (Panlab, S.L., Barcelona, Spain) in order to measure the total distance covered and to calculate the swimming speed. In the probe trial, the trajectories were analyzed to determine the number of annulus crossings, the time spent in each quadrant of the pool, as well as the incidence of non-goal directed (floating, wall hugging, chaining and random swimming) and goal-directed (scanning, focal searching and direct searching) search strategies 49 .
Protein extraction
A u t h o r ' s d r a f t v e r s i o n
Animals were sacrificed at the end of the behavioral tests, which is 5 days after administration of scFv-h3D6. The extraction was prepared by sequential centrifugation of brain subregions homogenates as previously described A u t h o r ' s d r a f t v e r s i o n Table 2 ) used to quantify the search strategy according to Lang et al., 2003 49 . 
Open-field test
Freezing and thigmotaxis
Initial freezing (latency, s) 1.73 ± 0.43 3.53 ± 0.26 *** 
